All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The gvhd Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the gvhd Hub cannot guarantee the accuracy of translated content. The gvhd and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View gvhd content recommended for you
The GvHD Hub are proud to present expert interviews directly from the 61st American Society of Hematology (ASH) meeting in Orlando, US. This interview with Arnon Nagler, Tel Aviv University, Tel Aviv, IL, was based on the question: How do you select the best graft-versus-host disease prophylaxis regimen?
Arnon Nagler explains the treatment landscape of GvHD prophylaxis. He describes the historical combination of cyclophosphamide and methotrexate for GvHD prevention. He also describes the big breakthrough of the anti-GvHD prophylaxis, post-transplant cyclophosphamide, that proved efficacious in the haploidentical setting, and also in the unrelated and sibling transplant setting. Arnon Nagler explains that shortly after transplant 50% of patients were able to discontinue immunosuppression when given post-transplant cyclophosphamide.
How to select the optimal GvHD prophylaxis regimen